Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bayer (DE:BAYN)
XETRA:BAYN
Bayer (BAYN) Stock Price & Analysis
430 Followers
BAYN Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€24.96 - €59.10
Previous Close€26.25
Volume871.08K
Average Volume (3M)4.71M
Market Cap
€25.79B
Enterprise Value€57.11B
Total Cash (Recent Filing)€10.15B
Total Debt (Recent Filing)€41.32B
Price to Earnings (P/E)-8.8
Beta0.84
Next Earnings
May 14, 2024EPS Estimate
€2.34Next Dividend Ex-DateN/A
Dividend Yield9.14%
Share Statistics
EPS (TTM)-2.99
Shares OutstandingN/A
10 Day Avg. Volume3,927,981
30 Day Avg. Volume4,710,940
Standard Deviation0.10
R-Squared0.22
Alpha-0.00738
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€30.71Price Target Upside16.82% Upside
Rating ConsensusHold
Number of Analyst Covering17
Bayer News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company expects Free Cash Flow to improve, reflecting a stronger financial position and the ability to invest in future growth.
Operational EfficiencyMomentum for the company is expected to improve with cost savings and easier comparables in the second half, potentially leading to better year-on-year dynamics.
Strategic ManagementCommendable organisational changes and significant savings under CEO Bill Anderson, enhancing the company's efficiency and competitiveness.
Bears Say
Financial PerformanceQ1 shows a potential slow start, with significant decline in earnings before interest, taxes, depreciation, and amortization (EBITDA) due to challenges in Crop Science and increased expenses.
Litigation RisksInvestor appetite for highly levered stocks is low and 3.7x net debt/EBITDA must be seen in conjunction with litigation risks from glyphosate and PCB.
Market CompetitionPharma's outlook remains cautious with expected flat organic growth and a forecasted significant drop in Xarelto revenues due to competition from generic products.
---
Options Prices
Currently, No data available
---
Ownership Overview
<0.01% Insiders
15.78% Mutual Funds
11.76% Other Institutional Investors
72.46% Public Companies and
Individual Investors
BAYN FAQ
What was Bayer’s price range in the past 12 months?
Bayer lowest stock price was €24.96 and its highest was €59.10 in the past 12 months.
What is Bayer’s market cap?
Currently, no data Available
When is Bayer’s upcoming earnings report date?
Bayer’s upcoming earnings report date is May 14, 2024 which is in 25 days.
How were Bayer’s earnings last quarter?
Bayer released its earnings results on Mar 05, 2024. The company reported €1.85 earnings per share for the quarter, beating the consensus estimate of €1.439 by €0.411.
Is Bayer overvalued?
According to Wall Street analysts Bayer’s price is currently Undervalued.
Does Bayer pay dividends?
Bayer does not currently pay dividends.
What is Bayer’s EPS estimate?
Bayer’s EPS estimate is €2.34.
How many shares outstanding does Bayer have?
Bayer has 982,424,100 shares outstanding.
What happened to Bayer’s price movement after its last earnings report?
Bayer reported an EPS of €1.85 in its last earnings report, beating expectations of €1.439. Following the earnings report the stock price went down -7.568%.
Which hedge fund is a major shareholder of Bayer?
Currently, no hedge funds are holding shares in DE:BAYN
---
Bayer Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.63%
12-Months-Change
Fundamentals
Return on Equity
-8.20%
Trailing 12-Months
Asset Growth
-5.76%
Trailing 12-Months
Company Description
Bayer
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides just over half of the company's sales and includes pharmaceutical drugs as well as vitamins. The company has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.
---
BAYN Stock 12 Months Forecast
Average Price Target
€30.71
▲(16.82% Upside)
Technical Analysis
Best Analysts Covering BAYN
1 Year
1 Year Success Rate
8/25 ratings generated profit
1 Year Average Return
-10.81%
reiterated a buy rating last month
Copying Peter Spengler's trades and holding each position for 1 Year would result in 32.00% of your transactions generating a profit, with an average return of -10.81% per trade.
---